Gilead Sciences (GILD) Short-Term Debt issuances (2012)
Gilead Sciences' (GILD) quarterly Short-Term Debt issuances came in at $149.0 million in Q3 2012, down 85.07% quarter-over-quarter from $997.9 million in Q1 2012.
Powered by 
Analysis
Gilead Sciences (GILD) Short-Term Debt issuances (2012) Analysis & Trends
Gilead Sciences (GILD) has reported Short-Term Debt issuances for 1 consecutive years, with $149.0 million the latest figure, recorded in Q3 2012.
- For the quarter ending Q3 2012, Short-Term Debt issuances changed N/A year-over-year to $149.0 million; the trailing twelve-month figure through Sep 2012 stood at $1.1 billion (changed N/A YoY), and the FY2010 full-year result was $500.0 million, up 25.0% from the prior year.
- Short-Term Debt issuances eased to $149.0 million in Q3 2012 per GILD's latest filing, from $997.9 million in the prior quarter.
- Across five years, Short-Term Debt issuances topped out at $997.9 million in Q1 2012 and bottomed at $149.0 million in Q3 2012.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Insmed | 27.67 Bn | 26.51 Bn | 358.27 Mn | - |